Compare Northrop Grumman Corporation (NOC) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Northrop Grumman Corporation vs Smith & Nephew plc — how do they compare? Northrop Grumman Corporation trades at $521.09 (market cap $73.16B), while Smith & Nephew plc trades at $27.67 (market cap $11.63B). The key difference: Northrop Grumman Corporation is far larger — about 6.3× Smith & Nephew plc's market cap, and Smith & Nephew plc pays the higher dividend (2.85%). Which is the better fit depends on your goals.
| NOC | SNN | |
|---|---|---|
Market Cap | $73.16B | $11.63B |
Sector | Industrials | Health |
52-Week High | $768.02 | $38.53 |
52-Week Low | $496.02 | $27.80 |
Enterprise Value | $87.14B | $14.66B |
Dividend Yield | 1.92% | 2.85% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Northrop Grumman (NOC) trades at $518.58, up 0.7% with strong earnings beats in recent quarters. Technical indicators show a bearish trend with oversold RSI signals, while fundamentals remain solid with 10.48% net margin and 26.96% ROE. The company maintains a record $105 billion backlog and raised guidance after strong Q2 results, supported by rising defense spending globally.
NOC presents a compelling value with a 16.37 P/E below industry averages and a $618.43 consensus price target implying 19% upside. Risks include execution on massive contracts and defense budget volatility, but analyst sentiment is strongly bullish with 57% buy ratings. The stock offers defensive growth exposure amid geopolitical tensions.
Smith & Nephew (SNN) trades at $27.87, down 3.46% over 24 hours and near its 52-week low. The stock shows a bearish technical trend with mixed sentiment; recent earnings have mostly beaten expectations, but Q2 2026 revenue growth missed and guidance was cut. Fundamentals are solid with revenue rising to $6.16B in 2025 and net income margin improving to 10.08%, though debt levels have increased. The company faces competitive pressures in key markets like U.S. Orthopaedics.
Outlook is cautious: valuation ratios like P/E of 18.96 are reasonable, but analyst consensus is Hold (65%) due to execution risks and CFO departure. Opportunities include innovation in surgical robotics and new product launches, but investors should monitor U.S. market weakness and debt management for sustained recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Northrop Grumman Corporation
Northrop Grumman is a defense contractor that is diversified across short-cycle and long-cycle businesses. The firm's segments include aeronautics, mission systems, defense services, and space systems. The company's aerospace segment creates the fuselage for the massive F-35 program and produces various piloted and autonomous flight systems. Mission systems creates a variety of sensors and processors for defense hardware. The defense systems segment is a long-range missile manufacturer. Finally, the company's space systems segment produces various space structures, sensors, and satellites.
Read more on NOC →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
